QuidelOrtho Corporation which can be found using ticker (QDEL) have now 6 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 173 and 85 calculating the mean target price we have $124.50. Given that the stocks previous close was at $83.90 this now indicates there is a potential upside of 48.4%. Also worth taking note is the 50 day moving average now sits at $85.05 and the 200 moving average now moves to $87.09. The market cap for the company is 5.48B. The stock price for the company is currently 82.26 USD
The potential market cap would be $8,133,710,847 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 49.38 and a 5.28% return on assets.
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.
